NOX2 deficiency protects against streptozotocin-induced β cell destruction and development of diabetes in mice

Fu-Li Xiang, Xiangru Lu, Brenda Strutt, David J. Hill, Qingping Feng

Departments of Medicine, Physiology and Pharmacology, University of Western Ontario, Lawson Health Research Institute, London, Ontario, Canada

Running Head: NOX2 and STZ-induced diabetes

Correspondence to:
Dr. Qingping Feng
E-mail: qfeng@uwo.ca

Submitted 22 October 2009 and accepted 8 July 2010.

This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
Objective: The role of NOX2-containing NADPH oxidase in the development of diabetes is not fully understood. We hypothesized that NOX2 deficiency decreases reactive oxygen species (ROS) production and immune response, and protects against streptozotocin (STZ)-induced β cell destruction and development of diabetes in mice.

Research Design and Methods: Five groups of mice, wild-type (WT), NOX2\(^{-/-}\), WT treated with apocynin, and WT adoptively transferred with NOX2\(^{-/-}\) or WT splenocytes were treated with multiple-low-dose STZ. Blood glucose and insulin levels were monitored and intra-peritoneal glucose tolerance test was performed. Isolated WT and NOX2\(^{-/-}\) pancreatic islets were treated with cytokines for 48 hours.

Results: Significantly lower blood glucose levels, higher insulin levels and better glucose tolerance was observed in NOX2\(^{-/-}\) mice and in WT mice adoptively transferred with NOX2\(^{-/-}\) splenocytes compared to respective control groups after STZ treatment. Compared with WT, β cell apoptosis, as determined by TUNEL staining, and insulitis were significantly decreased while β cell mass was significantly increased in NOX2\(^{-/-}\) mice. In response to cytokine stimulation, ROS production was significantly decreased and insulin secretion was preserved in NOX2\(^{-/-}\) compared to WT islets. Furthermore, pro-inflammatory cytokine release induced by concanavalin A was significantly decreased in NOX2\(^{-/-}\) compared to WT splenocytes.

Conclusions: NOX2 deficiency decreases β cell destruction and preserves islet function in STZ-induced diabetes by reducing ROS production, immune response and β cell apoptosis.

Type 1 diabetes is a T cell-mediated autoimmune disease characterized by the selective destruction of insulin-secreting β cells in islets of Langerhans. It is a multi-factorial process involving auto-antigen presentation by macrophages, dendritic cells and B cells, activation of autoreactive CD4\(^{+}\) T cells, activation and recruitment of β cell-specific CD8\(^{+}\) T cells, leading to increased cytokine and reactive oxygen species (ROS) production and destruction of β cells (1). The mechanisms of putative type 1 diabetes induced by multiple-low-dose streptozotocin (STZ) includes the direct β cell destruction, which is mainly induced via DNA alkylation (2) and the indirect β cell destruction from T cell-dependent immune reaction (3). Furthermore, in response to cytokine stimulation including interleukin (IL)-1β, interferon (IFN)-γ and tumor necrosis factor (TNF)-α, β cells also generate ROS and reactive nitrogen species (RNS) which may facilitate their destruction (4). Additionally, over-expression of anti-oxidant enzymes including superoxide dismutase (SOD), catalase, and glutathione peroxidase 1 (Gpx1) protects against the onset and development of diabetes and supports an important role of ROS in the pathogenesis of immune-mediated diabetes (5-12). NADPH oxidase is one of the main sources of superoxide radical formation in many cell types including phagocyte and β cells (13). This ROS producing enzyme consists of two membrane subunits (NOX2 and p22\(^{phox}\)), and at least four cytosolic components (p40\(^{phox}\), p47\(^{phox}\), p67\(^{phox}\) and Rac1). NADPH oxidase is a highly regulated enzyme. In the resting cells, the cytosolic complex is separated from the membrane-bound catalytic core. Upon stimulation, the cytosolic component p47\(^{phox}\)
becomes phosphorylated and the cytosolic complex migrates and binds to the membrane subunits to assemble into an active oxidase (14). It catalyzes the reduction of oxygen to superoxide anion using NADPH as a substrate and plays a major role in antimicrobial host defense as well as in tissue damage of autoimmune diseases (15; 16). NOX2 is one of the critical subunits of NADPH oxidase. T cells deficient in NOX2 exhibit an impaired ability to produce superoxide in response to anti-CD3 stimulation (17). Furthermore, glucose stimulates β cell superoxide production, which can be inhibited by a selective NADPH oxidase inhibitor diphenylene iodonium (DPI), suggesting a functional NADPH oxidase in the islet (18). However, a definitive role of NADPH oxidase in the development of diabetes remains to be determined.

In the present study, NOX2<sup>−/−</sup> mice were employed to investigate the role of NADPH oxidase in β cell destruction induced by multiple-low-dose STZ. We demonstrated that NOX2 deficiency attenuates the severity of hyperglycemia and the loss of β cell mass induced by STZ treatments via reduced ROS production and suppressed immune response.

**RESEARCH DESIGN AND METHODS**

**Animals.** NOX2<sup>−/−</sup> and C57BL/6 (wild-type, WT) mice were obtained from Jackson Laboratory (Bar Harbor, ME). Male NOX2<sup>−/−</sup> and WT mice of 8-12 weeks old were used in all experiments. Animals in this study were handled in accordance with the *Guide for the Care and Use of Laboratory Animals* published by the US National Institute of Health (NIH publication No. 85-23, revised 1996).

**Adoptive Transfer.** Single-cell suspensions were prepared from spleens of NOX2<sup>−/−</sup> and WT mice as previously described (19). Briefly, spleens were removed, minced and filtered through sterile 100 µm filters. Erythrocytes were lysed, and the nucleated cells were washed re-suspended in saline and injected via the lateral tail vein into irradiated (970 cGy) WT mice (10<sup>7</sup> cell/mouse). Mice received NOX2<sup>−/−</sup> and WT splenocytes were termed WT<sup>NOX2−/−</sup> and WT<sup>WT</sup>, respectively. These mice were allowed to recover for 5 weeks before the induction of diabetes.

**Streptozotocin diabetes model.** To induce diabetes, WT, NOX2<sup>−/−</sup>, WT treated with apocynin (10 mg/day/kg body weight, i.p.), WT<sup>NOX2−/−</sup> and WT<sup>WT</sup> mice were treated with STZ (80 mg/kg body weight, i.p. for 3 consecutive days). Additionally, some WT, NOX2<sup>−/−</sup> mice were treated with saline as vehicle controls. Random blood glucose levels were monitored on day 2, 5, 8 after the final injection of STZ with a glucose meter (OneTouch Ultra2, LifeScan Canada, Burnaby, BC). On day 9, intraperitoneal glucose tolerance test (IPGTT) was performed using an i.p. injection of D-glucose at 2 g/kg body weight after 16 hours fasting. Blood glucose was analyzed at 0, 15, 30, 60 and 120 minutes after glucose introducing. Non-fasting serum was collected. Pancreases were weighed and collected. Diabetic hyperglycemia was defined as a non-fasting blood glucose concentration greater than 11.1 mM for 2 or more consecutive tests.

**Alloxan diabetes model.** WT, NOX2<sup>−/−</sup> mice were treated with alloxan (60 mg/kg body weight, i.v.). Fasting blood glucose levels were measured and IPGTT was performed as described above. Non-fasting serum was collected for measurement of insulin levels.

**Measurement of β cell and islet mass, insulitis and apoptosis.** Pancreata from WT and NOX2<sup>−/−</sup> mice sacrificed on day 9 were fixed in 4% paraformaldehyde for 24 hours, embedded in paraffin and serially cut into 5 µm sections at 50 µm intervals. Immunostaining was performed with an anti-mouse insulin antibody (1:2000, Sigma, Oakville, Ontario) using a mouse on mouse immunodetection kit (Vector Laboratories, Burlingame, CA). The staining was visualized...
using diaminobenzidine. Sections were then counterstained with hematoxylin. The microscopic images were taken by a Zeiss microscope and analysed using AxioVision software. Insulin-positive cells were considered functional β cells. Relative β cell and islet area to total pancreatic area ratios were calculated. The β cell and islet mass were then evaluated by multiplying the area ratio with the pancreatic weight. The evaluation of insulitis score were assigned using the following scale: 0, intact islet; 1, peri-insulitis; 2, moderate insulitis (<50% of the islet infiltrated); 3, severe insulitis (≥50% of the islet infiltrated) as previously described (19). For the analysis of pancreatic islet apoptosis, double staining of in situ cell death detection fluorescein and insulin fluorescent immunohistochemistry (20) was performed. Pancreata from WT and NOX2−/− mice sacrificed 8 hours after the final injection of STZ were isolated, embedded and sectioned as described above. Apoptosis and necrosis of the islet cells were assessed via hematoxylin staining by the chromatin morphology (21).

Islet culture and treatment. Pancreatic islets were isolated from NOX2−/− and WT mice by liberase RI (Roche Diagnostics, Laval, QC) digestion as described previously (22). Isolated pancreatic islets were cultured free-floating in medium RPMI-1640 containing 11.1 mM glucose, supplemented with 2 mM L-glutamine, 10% fetal calf serum, 12 mM HEPES, 100 units/mL penicillin and 100 µg/mL streptomycin in an atmosphere of 95% air and 5% CO2 at 37°C overnight. Groups of 20 islets were then incubated in 200 µL DMEM medium containing 11.1 mM glucose supplemented with 2 mM L-glutamine, 10% fetal calf serum, 100 units/mL penicillin and 100 µg/mL streptomycin with or without cytokine mixture which was consisted of human recombinant IL-1β, IFN-γ and TNF-α (2 ng/mL each, Sigma, Oakville, Ontario) for 48 hours at 37°C in 5%CO2.

Determination of glucose-stimulated insulin release. Insulin secretion assay was performed as previously described (23). Briefly, islets from each experiment group were incubated in Kreb’s-Ringer bicarbonate buffer supplemented with 2 mg/mL bovine serum albumin (BSA) and 1.67 mM glucose for 30 minutes, followed by a 90-minute incubation in KRBH buffer supplemented with 2 mg/mL BSA and in the presence of 1.67 or 16.7 mM glucose. Insulin released during the 90 minutes was then measured and normalized by the DNA content of each 20-islet group. DNA content was determined by CyQUANT cell proliferation assay kit (Invitrogen Canada, Burlington, ON).

Detection of total ROS and superoxide production. Total ROS production in isolated islets was determined by dichlorofluorescein diacetate (DCF-DA) assay. Islets were homogenized in 100 µL RIP buffer (50 mM Tris-HCL PH 7.5, 50mM KCL and 10 mM MgCl2) and incubated with 10 µM DCF-DA at 37°C for 3 hours. Fluorescence was measured by excitation (485 nm) and emission (525 nm) spectra with a microplate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA). Superoxide production in serum and isolated islets was determined by dihydroethidium (DHE) assay. Serum and islets were incubated with 50 µM DHE at 37°C for 30 minutes. Fluorescence was measured by excitation (396 nm) and emission (579 nm) spectra, which detects 2-hydroxyethidium (a specific superoxide-derived DHE product) (24), using a microplate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA). Superoxide production in splenocytes in response to concanavalin A (ConA) was measured by lucigenin assay (25). Briefly, 10⁶ splenocytes were treated with ConA (5 µg/mL) with or without 0.1 µM DPI (NADPH inhibitor) for 5 minutes at 37°C followed by 50 µM lucigenin. Luminescence was then measured using a microplate reader.
(SpectraMax M5, Molecular Devices, Sunnyvale, CA).

**Determination of cytokine release from splenocytes.** Isolated splenocytes (5x10^6) from WT and NOX2^-/- mice were cultured overnight and then incubated with concanavalin A (ConA, 5µg/mL) for 48 hours. TNF-α and IL-1β release in the media was determined by ELISA kit (eBioscience, San Diego, CA).

**Measurement of serum insulin and total antioxidant levels.** Culture media of isolated islets in response to a 90-minute stimulation of 16.7 mM glucose were collected. Serum from non-fasting mice was obtained. Both culture media and serum were stored in -20 ºC and their insulin concentrations were measured by a mouse insulin ELISA kit (ALPCO, Salem, NH). Serum insulin levels were expressed as µg/L. Insulin concentrations in the culture media were adjusted by DNA content of the islets and expressed as ng/100 µg islet DNA/90 minutes. Serum total antioxidant levels were detected by total antioxidant capacity assay kit (Abcam, Cambridge, MA) and expressed as mM Trolox equivalent (mEq Trolox/L).

**Western blot analysis.** Antioxidant enzymes manganese SOD (SOD-2) and Gpx1 protein levels were assessed by western blotting. Briefly, cell lysates containing 80 µg of protein were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 12% gels, followed by electrophoretic transfer to nitrocellulose membranes. Blots were probed with antibodies against SOD-2 (1:1000; Santa Cruz Biotechnology, CA), Gpx1 (1:500; Abcam Inc. MA) and GAPDH (1:8000; Santa Cruz Biotechnology, CA) followed by incubation with horseradish peroxidase-conjugated secondary antibodies (1:2000; Santa Cruz Biotechnology, CA). Protein bands were detected using enhanced chemiluminescence method.

**Statistical analysis.** Data are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA for multiple group comparisons followed by Bonferroni correction or Student t-test for comparison between two groups. Difference in insulitis score between NOX2^-/- and WT mice was analyzed by the Chi-square test. A P value of less than 0.05 was considered statistically significant.

**RESULTS**

**NOX2 deficiency decreases STZ-induced hyperglycaemia.** Under normal condition, adult WT and NOX2^-/- mice showed equivalent levels of random blood glucose, serum superoxide, antioxidant and insulin (Figure 1). Two days after the final injection of STZ, 5 out of 7 WT mice developed hyperglycemia while only 1 of 7 NOX2^-/- mice had blood glucose level above 11.1 mmol/L. On day 5, all WT mice became diabetic but there were still 2 out of 7 NOX2^-/- that demonstrated normal blood glucose levels. Compared to WT, NOX2^-/- mice presented significantly lower random (Figure 1A, B) and fasting (Figure 1E) blood glucose levels after STZ treatment (P<0.01). Consistently, the results of IPGTT performed on day 9 as an in vivo measure of β cell function showed that STZ-induced glucose intolerance was significantly ameliorated in NOX2^-/- mice (P<0.01, Figure 1C, D). Similar effect was also observed in WT mice treated with an NADPH oxidase inhibitor, apocynin (10 mg/kg body weight/day). In concordance to the blood glucose level results, the serum insulin level was restored in NOX2^-/- mice compared to WT (P<0.05, Figure 1F). Serum superoxide production significantly increased after STZ treatment in both WT and NOX2^-/- mice (Figure 1G). However, compared to WT, NOX2^-/- mice presented significantly lower serum superoxide levels (P<0.01, Figure 1G). No significant changes were observed in serum antioxidant activity levels or protein expression of antioxidant enzymes including...
SOD-2 and Gpx1 after STZ treatment (Figure 1H-J).

**NOX2 deficiency improves β cell survival after STZ treatment.** Apoptosis is an important mechanism in the development of diabetes. We examined β cell apoptosis 9 days after STZ treatment by TUNEL staining and co-staining with insulin. Apoptotic β cells were detected by immunofluorescence associated with fragmented DNA (Figure 2A). Compared to WT, there were significantly less TUNEL-positive β cells in NOX2−/− mouse islets 9 days after STZ treatment (P<0.01, Figure 2B). Acute cell death in islets after STZ treatment was also investigated. Eight hours after the final STZ injection, a significant decrease in the number of apoptotic and necrotic cells in the islets was observed in NOX2−/− compared to WT mice (P<0.01, Figure 2C). Furthermore, necrosis was about 15 fold higher than apoptosis at this early stage of STZ-induced islet damage (Figure 2C).

**NOX2 deficiency preserves β cell mass after STZ treatment.** STZ treatment caused destruction of pancreatic β cells (representative histological images of pancreatic tissue are shown in Figure 3A). In WT, the number of functional (insulin immuno-positive) β cells within islets was markedly decreased as a result of STZ treatment. However in NOX2−/− mice, β cells appeared to be protected following the same dose regimen of STZ treatment (Fig. 3A). Compared to controls, β cell mass was significantly decreased in WT mice after STZ treatment (P<0.01). However, NOX2 deficiency significantly preserved the β cell mass (P<0.05, Figure 3B).

**NOX2 deficiency attenuated islet insulitis after STZ treatment.** Insulitis is an important process in β cell destruction induced by STZ. A scoring system was employed to evaluate the extent of insulitis after STZ treatment. Example of each score grade was shown in Figure 4A. Histological analysis showed the presence of insulitis in both groups of mice, with significant differences in the degree of leukocyte infiltration (P<0.01). In NOX2−/− mice, 43% of islets exhibited no insulitis, with 38% of islets showing only peri-insulitis. However, in WT mice, half of the islets showed grade 2-3 insulitis (Figure 4B).

**NOX2 deficiency improves islet function and decreases ROS production during cytokine treatment in vitro.** Islets isolated from WT and NOX2−/− mice showed a similar level of insulin release in respond to glucose stimulation (Figure 5A). The cytokine treatment (2 ng/mL each of IL-1β, IFN-γ and TNF-α) significantly decreased insulin release from the WT islets (P<0.01). However, this impairment was abrogated in NOX2−/− islets (P<0.01, Figure 5A). Cytokine treatment significantly increased total ROS and superoxide production in both WT and NOX2−/− islets (P<0.01). When compared to WT, both total ROS (Figure 5B) and superoxide (Figure 5C) levels of NOX2−/− islets were significantly decreased (P<0.01).

**NOX2 deficiency of the immune system decreases STZ-induced hyperglycemia.** Adoptive transfer was employed to replace the WT immune environment with a NOX2 deficient one. Five weeks after adoptive transfer, basal blood glucose levels of WTWT and WTNOX2−/− mice remained normal. STZ treatment induced a severe hyperglycemia in WTWT mice. However, the WTNOX2−/− mice demonstrated a significantly lower level of random blood glucose (Figure 6A and B, P<0.01) and fasting blood glucose (Figure 6E, P<0.01), higher serum insulin level (Figure 6F, P<0.01) as well as less intolerant to IPGTT compared to WTWT (Figure 6C and D, P<0.05). WT and NOX2−/− splenocytes employed to perform the adoptive transfer were stimulated with ConA. Superoxide production detected by lucigenin assay in response to ConA stimulation was significantly attenuated in NOX2−/− splenocytes compared to WT (P<0.01, Figure
Moreover, 48 hours after ConA stimulation, the pro-inflammatory cytokine release (TNF-α and IL-1β) was significantly impaired in NOX2−/− splenocytes compared to WT (P<0.05, Figure 6H and I).

**NOX2 deficiency prevents alloxan-induced diabetes.** After alloxan treatment (60 mg/kg, i.v.), all WT mice developed hyperglycemia while none of the NOX2−/− mice had blood glucose levels above 11.1 mmol/L on day 2 and 5. NOX2−/− mice presented significantly lower random (Figure 7A, B) and fasting (Figure 7E) blood glucose levels compared to WT (P<0.01). Consistently, IPGTT performed on day 9 showed that alloxan-induced glucose intolerance was abrogated in NOX2−/− mice (P<0.01, Figure 7C, D). Furthermore, serum insulin levels were significantly increased in NOX2−/− compared to WT mice after alloxan treatment (P<0.01, Figure 7F).

**DISCUSSION**

In the present study, we demonstrated for the first time that deficiency of NOX2 protects against the onset and development of STZ-induced diabetes in mice. STZ-induced hyperglycaemia was significantly inhibited in NOX2−/− compared to WT mice. In agreement with the blood glucose levels, the in vivo islet function measured by IPGTT and the serum insulin levels after STZ treatment was restored in NOX2−/− mice. Histological investigation of pancreatic tissue revealed that majority of β cells in WT pancreatic islets were destroyed by the STZ while the β cell mass was well-preserved in NOX2−/− mice. These data clearly showed the protective effects of NOX2 deficiency against STZ-induced diabetes, suggesting a critical role of NOX2-containing NADPH oxidase in β cell destruction in diabetes.

In the multiple-low-dose STZ model, diabetes is induced by two main mechanisms (3; 26; 27). One is the direct cytotoxic effect of STZ on β cells by alkylation of nuclear and mitochondrial DNA. The other is the local infiltration in the pancreatic islets and inflammation by mononuclear cells including lymphocytes and macrophages, which simulate the autoimmune reaction in type 1 diabetes (28). Although ROS has been implicated in both mechanisms, the source of the ROS production during development of diabetes is still not clear. Recently, functional phagocyte-like NADPH oxidase has been found in T (17) and β cells (18). NOX has been shown to be quantitatively an important source of ROS in pancreatic islets (18; 29). In the present study, cell death at 8 hours following the third STZ treatment was significantly decreased in the NOX2−/− mice. Although cytokine (IL-1β, IFN-γ and TNF-α) treatment significantly increased total ROS and superoxide production of the WT islets, both total ROS and superoxide levels were significantly decreased in the NOX2−/− islets. Furthermore, β cell function in terms of insulin release was well preserved in NOX2−/− islets. Additionally, serum insulin levels and IPGTT were restored in NOX2−/− mice following STZ treatment in vivo. These data suggest that NOX2-containing NADPH oxidase plays an important role not only in the early islet cell death from STZ but also cytokine-mediated ROS production in the islets leading to impairment of β cell function.

Alloxan is another diabetogenic chemical used frequently because of its ability to selectively damage β cells by inducing ROS formation (3). To further demonstrate that decreased ROS production due to NOX2 deficiency protects against diabetes, the alloxan diabetes model was used. Results showed that NOX2 deficiency protects against diabetes development after alloxan treatment. Our data provide convincing evidence for an important role of NOX2-mediated ROS production in diabetes development.

Type 1 diabetes is an autoimmune disease. Activation and recruitment of immune cells including β cell specific CD8+ T cells have been implicated in the pathogenesis
NOX2 and STZ-induced diabetes

of diabetes through cytokine expression and ROS production leading to β cell destruction (1). In fact, recent studies have shown that T cells have functional NADPH oxidase enzyme and deficiency in NOX2 decreases their ability to produce ROS according to antigen stimulation (17). In the present study we isolated splenocytes and measured ConA-stimulated superoxide production and pro-inflammatory cytokine release, which reflect immune cell activation. Our data showed that superoxide production and pro-inflammatory cytokine release (TNF-α and IL-1β) were significantly decreased in NOX2 deficient splenocytes. To further investigate the contribution of NOX2 in immune cells to functional impairment and damage of β cells, NOX2−/− splenocytes were adoptively transferred into lethally irradiated WT mice to reproduce the altered immune system in the NOX2 animals. Consistent with our hypothesis, a significantly lower blood glucose level, higher serum insulin level and better islet function were observed in the WT mice repopulated with NOX2 splenocytes compared to the control group after STZ treatment. Our results suggest that NOX2-containing NADPH oxidase in the activated immune cells including T cells also plays a key role in the impairment of islet function after STZ treatment.

In type 1 diabetes and animal models of STZ-induced diabetes, leukocytic infiltration (insulitis) and the production of pro-inflammatory cytokines contribute significantly to β cell destruction (30-32). Infiltrated macrophages and T cells generate cytotoxic mediators including cytokines and induce β cell death through apoptosis (33; 34). In our study, decreased insulitis and apoptosis were observed in the islets of NOX2−/− mice, leading to the well-preserved β cell mass after STZ treatment, which can be explained by a reduction of early islet cell death and the decreased ability of NOX2−/− splenocytes to produce superoxide and release pro-inflammatory cytokines. Previous studies have also shown that NOX2 deficiency results in decreased superoxide production from polymorphonuclear neutrophils and macrophages (34) and decreased hydrogen peroxide generation from T cells (17). Antigen presenting cells deficient in NOX2 have an impaired ability to present antigens due to enhanced antigen degradation (35). Additionally, peripheral blood memory B cell compartment is reduced in patients with chronic granulomatous disease (CGD) which mainly results from NOX2 deficiency (36). Taken together, NOX2 deficiency protects against β cells destruction and preserves islet function in the STZ-induced diabetes by inhibiting insulitis. These beneficial effects are likely due to less early β cell death from toxic effects of STZ and an inhibition of immune reaction including decreased antigen presentation, impaired immune cell activation and suppression of cytotoxic effects from T cells, neutrophils and macrophages during development of diabetes.

In conclusion, our study demonstrated that NOX2 deficiency attenuates the severity of hyperglycemia, β cell mass loss and insulitis in the multiple-low-dose STZ-induced diabetes in mice. The protective effects are a result of decreased β cell apoptosis, decreased ROS production from the islets and suppressed immune response. The ability of NOX2 in regulating the immune response in this model supports an important role of NOX2-containing NADPH oxidase in the development of diabetes induced by STZ. NOX2 may represent a potential therapeutic target for treatment of diabetes.

Author contributions. F.L.X. researched data and wrote manuscript. X.L. reviewed/editing manuscript. B.S. researched data. D.H. reviewed/editing manuscript. Q.F. wrote manuscript.
ACKNOWLEDGEMENTS

This study was supported by grants from the Canadian Institutes of Health Research (MOP-14653 to QF) and the Heart & Stroke Foundation of Ontario (HSFO, T-6040 to QF).

Fu-Li Xiang is supported by a Doctoral Research Award from the Heart & Stroke Foundation of Canada. Dr. Feng is a HSFO Career Investigator.

REFERENCES

1. Yoon JW, Jun HS: Autoimmune destruction of pancreatic beta cells. Am J Ther 12:580-591, 2005
2. Masutani M, Suzuki H, Kamada N, Watanabe M, Ueda O, Nozaki T, Jishage K, Watanabe T, Sugimoto T, Nakagama H, Ochiya T, Sugimura T: Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96:2301-2304, 1999
3. Lenzen S: The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 51:216-226, 2008
4. Mathews CE, Suarez-Pinzon WL, Baust JJ, Strynadka K, Leiter EH, Rabinovitch A: Mechanisms underlying resistance of pancreatic islets from ALR/Lt mice to cytokine-induced destruction. J Immunol 175:1248-1256, 2005
5. Harmon JS, Bogdani M, Parazzoli SD, Mak SS, Oseid EA, Berghmans M, Leboeuf RC, Robertson RP: beta-Cell-specific overexpression of glutathione peroxidase preserves intranuclear MaF and reverses diabetes in db/db mice. Endocrinology 150:4855-4862, 2009
6. Kubisch HM, Wang J, Bray TM, Phillips JP: Targeted overexpression of Cu/Zn superoxide dismutase protects pancreatic beta-cells against oxidative stress. Diabetes 46:1563-1566, 1997
7. Chen H, Carlson EC, Pellet L, Moritz JT, Epstein PN: Overexpression of metallothionein in pancreatic beta-cells reduces streptozotocin-induced DNA damage and diabetes. Diabetes 50:2040-2046, 2001
8. Azevedo-Martins AK, Lortz S, Lenzen S, Curi R, Eizirik DL, Tiedge M: Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-kappaB activation in insulin-producing cells. Diabetes 52:93-101, 2003
9. Lortz S, Tiedge M, Nachtwey T, Karlsten AE, Nerup J, Lenzen S: Protection of insulin-producing RINm5F cells against cytokine-mediated toxicity through overexpression of antioxidant enzymes. Diabetes 49:1123-1130, 2000
10. Tiedge M, Lortz S, Munday R, Lenzen S: Protection against the co-operative toxicity of nitric oxide and oxygen free radicals by overexpression of antioxidant enzymes in bioengineered insulin-producing RINm5F cells. Diabetologia 42:849-855, 1999
11. Hotta M, Tashiro F, Ikegami H, Niwa H, Ogihara T, Yodoi J, Miyazaki J: Pancreatic beta cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med 188:1445-1451, 1998
12. Xu B, Moritz JT, Epstein PN: Overexpression of catalase provides partial protection to transgenic mouse beta cells. Free Radic Biol Med 27:830-837, 1999
13. Newsholme P, Morgan D, Rebelato E, Oliveira-Emilio HC, Procopio J, Curi R, Carpinelli A: Insights into the critical role of NADPH oxidase(s) in the normal and dysregulated pancreatic beta cell. Diabetologia 52:2489-2498, 2009
14. Babior BM, Lambeth JD, Nauseef W: The neutrophil NADPH oxidase. *Arch Biochem Biophys* 397:342-344, 2002
15. Lambeth JD: NOX enzymes and the biology of reactive oxygen. *Nat Rev Immunol* 4:181-189, 2004
16. Segal AW: How neutrophils kill microbes. *Annu Rev Immunol* 23:197-223, 2005
17. Jackson SH, Devadas S, Kwon J, Pinto LA, Williams MS: T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. *Nat Immunol* 5:818-827, 2004
18. Oliveira HR, Verlengia R, Carvalho CR, Britto LR, Curi R, Carpinelli AR: Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. *Diabetes* 52:1457-1463, 2003
19. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, Corneli RB, Ferretti E, Gulino A, Grasso F, De Simone C, Di Mario U, Falorni A, Boirivant M, Dotta F: Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. *Diabetologia* 48:1565-1575, 2005
20. Feng Q, Song W, Lu X, Hamilton JA, Lei M, Peng T, Yee SP: Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. *Circulation* 106:873-879, 2002
21. Cardinal JW, Margison GP, Mynett KJ, Yates AP, Cameron DP, Elder RH: Increased susceptibility to streptozotocin-induced beta-cell apoptosis and delayed autoimmune diabetes in alkylpurine-DNA-N-glycosylase-deficient mice. *Mol Cell Biol* 21:5605-5613, 2001
22. Fujita H, Kakei M, Fujishima H, Morii T, Yamada Y, Qi Z, Breyer MD: Effect of selective cyclooxygenase-2 (COX-2) inhibitor treatment on glucose-stimulated insulin secretion in C57BL/6 mice. *Biochem Biophys Res Commun* 363:37-43, 2007
23. Flodstrom M, Tyrberg B, Eizirik DL, Sandler S: Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. *Diabetes* 48:706-713, 1999
24. Robinson KM, Janes MS, Pehar M, Monette JS, Ross MF, Hagen TM, Murphy MP, Beckman JS: Selective fluorescent imaging of superoxide in vivo using ethidium-based probes. *Proc Natl Acad Sci U S A* 103:15038-15043, 2006
25. Peng T, Lu X, Feng Q: Pivotal role of gp91phox-containing NADH oxidase in lipopolysaccharide-induced tumor necrosis factor-alpha expression and myocardial depression. *Circulation* 111:1637-1644, 2005
26. Paik SG, Fleischer N, Shin SI: Insulin-dependent diabetes mellitus induced by subdiabetogenic doses of streptozotocin: obligatory role of cell-mediated autoimmune processes. *Proc Natl Acad Sci U S A* 77:6129-6133, 1980
27. Bonnevie-Nielsen V, Steffes MW, Lernmark A: A major loss in islet mass and B-cell function precedes hyperglycemia in mice given multiple low doses of streptozotocin. *Diabetes* 30:424-429, 1981
28. Like AA, Rossini AA: Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. *Science* 193:415-417, 1976
29. Morgan D, Oliveira-Emilio HR, Keane D, Hirata AE, Santos da Rocha M, Bordin S, Curi R, Newsholme P, Carpinelli AR: Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. *Diabetologia* 50:359-369, 2007
30. Fukuda K, Tesch GH, Yap FY, Forbes JM, Flavell RA, Davis RJ, Nikolic-Paterson DJ: M KK3 signalling plays an essential role in leukocyte-mediated pancreatic injury in the multiple low-dose streptozotocin model. Lab Invest 88:398-407, 2008

31. Hohmeier HE, Tran VV, Chen G, Gasa R, Newgard CB: Inflammatory mechanisms in diabetes: lessons from the beta-cell. Int J Obes Relat Metab Disord 27 Suppl 3:S12-16, 2003

32. Kawasaki E, Abiru N, Eguchi K: Prevention of type 1 diabetes: from the view point of beta cell damage. Diabetes Res Clin Pract 66 Suppl 1:S27-32, 2004

33. Mellado-Gil JM, Aguilar-Diosdado M: High glucose potentiates cytokine- and streptozotocin-induced apoptosis of rat islet cells: effect on apoptosis-related genes. J Endocrinol 183:155-162, 2004

34. Ostanin DV, Barlow S, Shukla D, Grisham MB: NADPH oxidase but not myeloperoxidase protects lymphopenic mice from spontaneous infections. Biochem Biophys Res Commun 355:801-806, 2007

35. Savina A, Jancic C, Hugues S, Guermonprez P, Vargas P, Moura IC, Lennon-Dumenil AM, Seabra MC, Raposo G, Amigorena S: NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 126:205-218, 2006

36. Bleesing JJ, Souto-Carneiro MM, Savage WJ, Brown MR, Martinez C, Yavuz S, Brenner S, Siegel RM, Horwitz ME, Lipsky PE, Malech HL, Fleisher TA: Patients with chronic granulomatous disease have a reduced peripheral blood memory B cell compartment. J Immunol 176:7096-7103, 2006

Figure Legends:

**Figure 1.** Blood glucose and serum insulin levels after multiple-low-dose STZ treatment. A and B: NOX2<sup>-/-</sup> mice and WT mice treated with apocynin (10 mg/kg body weight/day) showed a significant decrease in random blood glucose levels compared to WT after STZ treatment. C and D: An intra-peritoneal glucose tolerance test 9 days after STZ treatment revealed that glucose clearance was significantly improved in NOX2<sup>-/-</sup> and in WT mice treated with apocynin, compared to WT mice. E: NOX2<sup>-/-</sup> mice had a significantly lower fasting blood glucose level compared to WT after STZ treatment. F-H: After STZ treatment, serum insulin levels (F) in NOX2<sup>-/-</sup> mice were significantly higher and superoxide levels (G) were significantly lower than those in WT mice. No difference in blood glucose and serum insulin was found between control groups. Total antioxidant levels, SOD-2 and Gpx1 expression was similar between WT and NOX2<sup>-/-</sup> mice (H-J). Data are mean ± SEM, n=6-7 per group for A-H, n=4-5 per group for I and J. *P<0.05, ** P<0.01 vs. STZ-treated WT. AUC, area under the curve.

**Figure 2.** Islet cell apoptosis after multiple-low-dose STZ treatment. A: Representative histological TUNEL staining of WT and NOX2<sup>-/-</sup> mouse islets 9 days following STZ treatment. B: STZ-induced β cell apoptosis was significantly decreased in NOX2<sup>-/-</sup> compared to WT mice 9 days following STZ treatment. C: STZ-induced islet cell apoptosis and necrosis was both significantly decreased in NOX2<sup>-/-</sup> compared to WT mice directly after STZ treatment for 3 days. Data are mean ± SEM, n=5-7 per group, ** P<0.01 vs. STZ-treated WT.

**Figure 3.** β cell mass after multiple-low-dose STZ treatment. A: Representative histological insulin staining of pancreas sections from each experiment group. Insulin-positive cells, within islets are stained brown. B: No difference in β cell mass was found between control groups. Following STZ treatment, β cell mass was significantly preserved in NOX2<sup>-/-</sup> compared to WT.
mice. Data are mean ± SEM, n=4-6 per group, **P<0.01 vs. WT control; † P<0.05 vs. STZ-treated WT.

**Figure 4.** Islet insulitis after multiple-low-dose STZ treatment. A: Representative histological images are shown. The insulitis score was assigned using the following scale: 0, intact islet (A0); 1, peri-insulitis (A1); 2, moderate insulitis (A2, <50% of the islet infiltrated); 3, severe insulitis (A3, ≥50% of the islet infiltrated). B: Islets from 10 WT mice and 8 NOX2−/− mice were assigned insulitis scores. Less infiltration was found in NOX2−/− islets compared to WT after STZ treatment (P<0.01, Chi-square analysis). Data are mean ± SEM.

**Figure 5.** Isolated islet function and ROS production after cytokine treatment. A: Glucose-stimulated insulin release after treatment with combined cytokines for 48 h. Insulin release in response to 16.7 mmol/L glucose was significantly impaired in cytokine treated isolated WT islets compared to WT control but was well preserved in cytokine treated NOX2−/− islets. B: Total ROS production detected by DCF-DA in isolated islets treated with cytokines. After cytokine treatment, ROS in the islets significantly increased compared to control groups. NOX2−/− islets showed a significantly lower ROS production compared to WT. C: Superoxide production detected by DHE in isolated islets treated with cytokines. After cytokine treatment, superoxide production in the islets was significantly increased compared to control groups. NOX2−/− islets showed a significantly lower superoxide production compared to WT. Data are mean ± SEM, n=4-5 per group, **P<0.01 vs. WT control, † P<0.01 vs. cytokine-treated WT.

**Figure 6.** Effects of adoptive transfer with NOX2−/− splenocytes on β cell function after multiple-low-dose STZ treatment. A to F: Blood glucose and insulin levels after STZ treatment in mice that underwent adoptive transfer. WTNOX2−/− and WTWT indicate WT mice adoptively transferred with NOX2−/− and WT splenocytes, respectively. The WTNOX2−/− mice showed lower random (A and B) and fasting (E) blood glucose levels, and higher serum insulin level (F) compared to WTWT mice after STZ treatment. IPGTT results (C and D) demonstrated that the in vivo β cell function of WTNOX2−/− mice was significantly preserved than WTWT mice after STZ treatment. *P<0.05, **P<0.01 vs. WTWT. G to I, The ability of NOX2−/− splenocytes to produce ROS (G) and pro-inflammatory cytokines, TNF-α (H) and IL-1β (I) in response to ConA (5 µg/mL) simulation was significantly impaired compared to WT splenocytes. *P<0.05, **P<0.01 vs. WT. Data are mean ± SEM, n=4-6 per group. AUC, area under the curve.

**Figure 7.** Blood glucose and serum insulin levels after alloxan treatment. A and B: NOX2−/− mice showed significant decreased random blood glucose levels compared to WT after alloxan treatment. C and D: An intra-peritoneal glucose tolerance test at 9 days after alloxan treatment revealed that β cell function was significantly better in NOX2−/− compared to WT mice. E and F: NOX2−/− mice had a significantly lower fasting blood glucose level and higher serum insulin levels compared to WT after alloxan treatment. Data are mean ± SEM, n=6 per group, **P<0.01 vs. WT. AUC, area under the curve.
Figure 1

A. Random blood glucose levels

B. Area under the curve (AUC) for blood glucose

C. Blood glucose response to glucose load

D. AUC for blood glucose response to glucose load

E. Fasting blood glucose levels

F. Serum insulin levels

G. Serum triglycerides

H. Total superoxide dismutase activity

I. Western blot analysis of SOD2 and GAPDH

J. Western blot analysis of Opn1 and GAPDH

NOX2 and STZ-induced diabetes
Figure 2
A

|        | DAPI | Insulin | TUNEL | Merge |
|--------|------|---------|-------|-------|
| WT     | ![Image](image1.png) | ![Image](image2.png) | ![Image](image3.png) | ![Image](image4.png) |
| NOX2−/−| ![Image](image5.png) | ![Image](image6.png) | ![Image](image7.png) | ![Image](image8.png) |

(x630)

B

% TUNEL positive cells in islets

|        | WT     | NOX2−/− |
|--------|--------|---------|
|        | ![Graph](image9.png) | ![Graph](image10.png) |

C

Total islet cells (%)

|        | WT     | NOX2−/− |
|--------|--------|---------|
|        | ![Graph](image11.png) | ![Graph](image12.png) |

Figure 3
A

Control

|        | WT     | NOX2−/− |
|--------|--------|---------|
|        | ![Image](image13.png) | ![Image](image14.png) |

STZ

(x100)

B

β Cell Mass (mg)

|        | Control | STZ     |
|--------|---------|---------|
|        | ![Graph](image15.png) | ![Graph](image16.png) |
Figure 4

A

Score 0  Score 1

Score 2  Score 3

(x400)

B

Insulitis (% of islets)

WT   NOX2^{-/-}

Figure 5

A

Insulin Release

WT   NOX2^{-/-}

Control   Cytokine

B

total ROS Production

WT   NOX2^{-/-}

Control   Cytokine

C

Superoxide Production

WT   NOX2^{-/-}

Control   Cytokine
NOX2 and STZ-induced diabetes

Figure 6

A)  
B)  
C)  
D)  
E)  
F)  
G)  
H)  
I)  

16
Figure 7

A

Random Blood Glucose (mmol/L)

Days after alloxan injection

B

AUC

WT

NOX2<sup>-/-</sup>

C

Blood Glucose (mmol/L)

Minutes after glucose load

D

AUC

WT

NOX2<sup>-/-</sup>

E

Fasting Blood Glucose (mmol/L)

WT

NOX2<sup>-/-</sup>

F

Serum Insulin (μg/L)

WT

NOX2<sup>-/-</sup>